http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Heo, Jee-In,Oh, Soo-Jin,Kho, Yoon-Jung,Kim, Jeong-Hyeon,Kang, Hong-Joon,Park, Seong-Hoon,Kim, Hyun-Seok,Shin, Jong-Yeon,Lee, Sung-Young,Kim, Min-Ju,Min, Bon-Hong,Kim, Sung-Chan,Park, Jae-Bong,Kim, Jae The Korean Society for Integrative Biology 2010 Animal cells and systems Vol.14 No.4
PC12 cells were differentiated into the cells of chromaffin phenotype by butyrate treatment. Cells were aggregated and formed tight cell adhesion. To investigate the molecular change in this differentiation, we examined expression levels of cell adhesion proteins and extracellular proteins during butyrate induced-differentiation of PC12 cells. Integrin ${\beta}1$, integrin ${\alpha}7$, E cadherin, VCAM, collagen-I, fibronectin, desmoglein and connexin were increased during differentiation. The levels of clusterin and secreted clusterin were also increased. These increased levels of cell adhesion proteins and extracellular proteins appear to induce cell aggregation and tight cell adhesion. The levels of p21, p27 and p16 were increased probably because of differentiation-related growth arrest during differentiation. Prolonged incubation of butyrate up to 1 day was required for differentiation. Signal transduction pathways for this differentiatiom could not be identified since various inhibitors had no effect. The results showed that butyrateinduced differentiation of PC12 cells to chromaffin cells involves tight cell adhesion and induction of extracellular proteins and cell adhesion proteins.
Heo, Ju Sun,Choi, Ka Young,Sohn, Se Hyoung,Kim, Curie,Kim, Yoon Joo,Shin, Seung Han,Lee, Jae Myung,Lee, Juyoung,Sohn, Jin A,Lim, Byung Chan,Lee, Jin A,Choi, Chang Won,Kim, Ee-Kyung,Kim, Han-Suk,Kim, B The Korean Pediatric Society 2012 Clinical and Experimental Pediatrics (CEP) Vol.55 No.11
Mucolipidosis II (ML II) or inclusion cell disease (I-cell disease) is a rarely occurring autosomal recessive lysosomal enzyme-targeting disease. This disease is usually found to occur in individuals aged between 6 and 12 months, with a clinical phenotype resembling that of Hurler syndrome and radiological findings resembling those of dysostosis multiplex. However, we encountered a rare case of an infant with ML II who presented with prenatal skeletal dysplasia and typical clinical features of severe secondary hyperparathyroidism at birth. A female infant was born at $37^{+1}$ weeks of gestation with a birth weight of 1,690 g (<3rd percentile). Prenatal ultrasonographic findings revealed intrauterine growth retardation and skeletal dysplasia. At birth, the patient had characteristic features of ML II, and skeletal radiographs revealed dysostosis multiplex, similar to rickets. In addition, the patient had high levels of alkaline phosphatase and parathyroid hormone, consistent with severe secondary neonatal hyperparathyroidism. The activities of ${\beta}$-D-hexosaminidase and ${\alpha}$-N-acetylglucosaminidase were moderately decreased in the leukocytes but were 5- to 10-fold higher in the plasma. Examination of a placental biopsy specimen showed foamy vacuolar changes in trophoblasts and syncytiotrophoblasts. The diagnosis of ML II was confirmed via GNPTAB genetic testing, which revealed compound heterozygosity of c.3091C>T (p.Arg1031X) and c.3456_3459dupCAAC (p.Ile1154GlnfsX3), the latter being a novel mutation. The infant was treated with vitamin D supplements but expired because of asphyxia at the age of 2 months.
( Chan-young Ock ),( Shin-hye Yoo ),( Bhumsuk Keam ),( Miso Kim ),( Tae Min Kim ),( Yoon Kyung Jeon ),( Dong-wan Kim ),( Doo Hyun Chung ),( Dae Seog Heo ) 대한내과학회 2019 The Korean Journal of Internal Medicine Vol.34 No.5
Background/Aims: Although crizotinib is standard chemotherapy for advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), clinical factors affecting progression-free survival (PFS) have not been reported. The purpose of this study was to identify clinical factors affecting PFS of crizotinib and develop a prognostic model for advanced ALK-positive NSCLC. Methods: Clinicopathologic features of patients enrolled in PROFILE 1001, 1005, 1007, and 1014 (training cohort) were reviewed. We conducted multivariate Cox analysis for PFS and overall survival (OS) in the training cohort (n = 159) and generated a proportional hazards model based on significant clinicopathologic factors, and then validated the model in an independent validation cohort (n = 40). Results: In the training cohort, the objective response rate was 81.5%. Median PFS and OS from the start of crizotinib were 12.4 and 31.3 months, respectively. Multivariate Cox analysis showed poor performance status, number of metastatic organs (≥ 3), and no response to crizotinib independently associated shorter PFS. Based on a score derived from these three factors, median PFS and OS of patients with one or two factors were significantly shorter compared to those without these factors (median PFS, 22.4 months vs. 10.5 months vs. 6.5 months; median OS, not reached vs. 29.1 months vs. 11.8 months, respectively; p < 0.001 for each group). This model also had validated in an independent validation cohort. Conclusions: Performance status, number of metastatic organs, and response to crizotinib affected PFS of crizotinib in ALK-positive NSCLC. Based on these factors, we developed a simple and useful prediction model for PFS.
Heo You Joung,Yoo Jae Ho,Choe Yun Soo,Park Sang Hee,Lee Seung Bok,Kim Hyun A,Choi Jung Yoon,Lee Young Ah,Lim Byung Chan,Chueh Hee Won 대한소아내분비학회 2022 Annals of Pediatirc Endocrinology & Metabolism Vol.27 No.3
Mitotane is an adrenolytic drug that exhibits therapeutic effects within a narrow target range (14–20 μg/dL). Various complications develop if the upper limit is exceeded. We present the case of a 5-year-old girl with breast development, acne, and pubic hair who was diagnosed with an adrenal mass that was subsequently excised. The pathological finding was adrenocortical carcinoma with a high risk of malignancy, and adjuvant therapy (combined mitotane and radiation therapy) was recommended. Mitotane was initiated at a low dose to allow monitoring of the therapeutic drug level, and high-dose hydrocortisone was also administered. However, the patient exhibited elevated adrenocorticotropic hormone levels and vague symptoms such as general weakness and difficulty concentrating. It was important to determine if these symptoms were signs of the neurological complications that develop when mitotane level is elevated. Encephalopathy progression and pubertal signs appeared 6 months after diagnosis, induced by high mitotane level. The mitotane decreased to subtherapeutic level several months after its discontinuation, at which time endocrinopathy (central hypothyroidism, hypercholesterolemia, and secondary central precocious puberty) developed. The case shows that low-dose mitotane can trigger neurological and endocrinological complications in a pediatric patient, indicating that the drug dose should be individualized with frequent monitoring of the therapeutic level.
Hydrotropic magnetic micelles for combined magnetic resonance imaging and cancer therapy
Yoon, Hong Yeol,Saravanakumar, Gurusamy,Heo, Roun,Choi, Seung Hong,Song, In Chan,Han, Moon Hee,Kim, Kwangmeyung,Park, Jae Hyung,Choi, Kuiwon,Kwon, Ick Chan,Park, Kinam Elsevier 2012 Journal of controlled release Vol.160 No.3
<P><B>Abstract</B></P><P>Polymeric nanoparticles, capable of encapsulating imaging agents and therapeutic drugs, have significant advantages for simultaneous diagnosis and therapy. Nonetheless, improvements in the loading contents of the active agents are needed to achieve enhanced imaging and effective therapeutic outcomes. Aiming to make these improvements, a hydrotropic micelle (HM) was explored to encapsulate superparamagnetic iron oxide nanoparticles (SPIONs) as the magnetic resonance (MR) imaging agent and paclitaxel (PTX) as the hydrophobic anticancer drug. Owing to its hydrotropic inner core with hydrophobic nature, HM could effectively encapsulate both of PTX and SPION via the simple dialysis method. The hydrodynamic size of HM increased from 68 to 178nm after physical encapsulation of SPION and PTX. Transmission electron microscopy analysis of HM bearing SPION and PTX (HM-SPION-PTX) revealed a spherical morphology with SPION clusters in the micelle cores. The micelles released PTX in a sustained manner. The bare HM and HM-SPION showed no toxicity to SCC7 cells, whereas HM-PTX and HM-SPION-PTX showed dose-dependent cytotoxicity that was lower than free PTX. HM-SPION-PTX exhibited 8.1-fold higher <I>T</I><SUB>2</SUB> relaxivity than HM-SPION, implying potential of HM-SPION-PTX as the contrast agent for MR imaging. When systemically administered to tumor-bearing mice, HM-SPION-PTX was effectively accumulated at the tumor site, allowing its detection using MR imaging and effective therapy. Overall, these results suggested that HM-SPION-PTX is a promising candidate for combined diagnosis and treatment of cancer.</P> <P><B>Graphical abstract</B></P><P>Hydrotropic micelles bearing the MR contrast agents and paclitaxel allow for detection and effective therapy of tumor.<ce:figure id='f0005'></ce:figure></P>
Seokho Yoon,Suk Chan Kim,Jun Heo,Iickho Song,Sun Yong Kim IEEE 2009 IEEE Transactions on Vehicular Technology VT Vol.58 No.4
<P>As a novel code-acquisition scheme, the twin-cell detection (TCD) is proposed for the acquisition in time of spread-spectrum codes in the presence of fractional Doppler frequency offset (FDFO). When the FDFO exists, the correlation peak that is used for detection during the acquisition process is split into two neighboring peaks with smaller magnitudes, which results in a considerable degradation in the overall acquisition performance of conventional schemes. In the TCD, the decision variable for detection is formed by combining two consecutive correlator outputs so that the influence of the reduction in the correlation peak due to the FDFO can be alleviated. The numerical results show that the TCD can offer a better mean-time-to-synchronization performance than the conventional scheme based on the cell-by-cell detection.</P>
N-Type c-Si 이종접합 태양전지 제작을 위한 a-Si:H(p) 가변 최적화
허종규(Heo, Jong-Kyu),윤기찬(Yoon, Ki-Chan),최형욱(Choi, Hyung-Wook),이영석(Lee, Young-Suk),김영국(Kim, Young-Kuk),이준신(Yi, Jun-Sin) 한국신재생에너지학회 2009 한국신재생에너지학회 학술대회논문집 Vol.2009 No.06
Amorphous/crystalline silicon heterojunction solar cells, TCO/a-Si:H (p)/c-Si(n)/a-Si:H(n)/Al, are investigated. The influence of various parameters for the front structures was studied. We used thin (10 nm) a-Si:H(p) layers of amorphous hydrogenated silicon are deposited on top of a thick (500{mu}m) crystalline c-Si wafer. This work deals with the influence of the a-Si:H(p) doping concentration on the solar cell performance is studied.